BridgeBio Pharma CFO reports Form 4 stock sales and tax withholding

Q: How many BridgeBio (BBIO) shares were sold by the President and CFO?

The President and CFO sold 9,978 shares at a weighted average price of $66.1923 and 6,956 shares at a weighted average price of $66.8398 on 11/17/2025 .

Q: Were the BridgeBio (BBIO) stock sales made under a Rule 10b5-1 plan?

Yes. The sales reported for 11/17/2025 were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on March 31, 2025 .

Q: Why were 21,317 BridgeBio (BBIO) shares withheld on 11/16/2025?

The 21,317 shares of common stock were withheld to satisfy the reporting person's tax obligation related to the vesting of 38,547 restricted stock units.

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

BridgeBio Pharma, Inc. (BBIO) President and CFO reported stock transactions involving company common shares. On 11/16/2025, 21,317 shares were withheld to cover taxes upon vesting of 38,547 restricted stock units. On 11/17/2025, he sold 9,978 shares at a weighted average price of $66.1923 and 6,956 shares at a weighted average price of $66.8398, with sales executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 31, 2025. Following these transactions, he beneficially owns 382,830 BridgeBio common shares directly.

Insider Trade Summary

Net Seller: 16,934 shares ($1,125,404)

Net Sell 3 txns

Insider Trimarchi Thomas

Role President and CFO

Sold 16,934 shs ($1.13M)

Type	Security	Shares	Price	Value
Sale	Common Stock	9,978	$66.1923	$660K
Sale	Common Stock	6,956	$66.8398	$465K
Tax Withholding	Common Stock	21,317	$66.39	$1.42M

Holdings After Transaction: Common Stock — 389,786 shares (Direct)

Footnotes (1)

Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 38,547 shares of Common Stock underlying the Reporting Person's Restricted Stock Units. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025. Represents the weighted average sale price of the shares sold from $65.575 to $66.57 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $66.61 to $67.26 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

11/18/2025 - 07:28 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Trimarchi Thomas

(Last)

(First)

(Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO

94304

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President and CFO

3. Date of Earliest Transaction (Month/Day/Year)
11/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/16/2025		F		21,317⁽¹⁾	D	$66.39	399,764	D
Common Stock	11/17/2025		S⁽²⁾		9,978	D	$66.1923⁽³⁾	389,786	D
Common Stock	11/17/2025		S⁽²⁾		6,956	D	$66.8398⁽⁴⁾	382,830	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 38,547 shares of Common Stock underlying the Reporting Person's Restricted Stock Units.

2. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

3. Represents the weighted average sale price of the shares sold from $65.575 to $66.57 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

4. Represents the weighted average sale price of the shares sold from $66.61 to $67.26 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

Remarks:

	/s/ Will Solis, Attorney-in-Fact	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did BridgeBio Pharma (BBIO) disclose in this Form 4 filing?

The filing reports stock transactions by BridgeBio Pharma's President and CFO, including tax withholding shares from vested restricted stock units and open market sales of common stock.

How many BridgeBio (BBIO) shares were sold by the President and CFO?

The President and CFO sold 9,978 shares at a weighted average price of $66.1923 and 6,956 shares at a weighted average price of $66.8398 on 11/17/2025.

Were the BridgeBio (BBIO) stock sales made under a Rule 10b5-1 plan?

Yes. The sales reported for 11/17/2025 were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on March 31, 2025.

Why were 21,317 BridgeBio (BBIO) shares withheld on 11/16/2025?

The 21,317 shares of common stock were withheld to satisfy the reporting person's tax obligation related to the vesting of 38,547 restricted stock units.

How many BridgeBio (BBIO) shares does the President and CFO own after these transactions?

After the reported transactions, the President and CFO beneficially owns 382,830 shares of BridgeBio Pharma common stock directly.

What is the role of the reporting person in BridgeBio Pharma (BBIO)?

The reporting person is an officer of BridgeBio Pharma, serving as President and CFO.